SLE

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alumis
AlumisSOUTH SAN FRANCISCO, CA
1 program
1
ESK-001Phase 21 trial
Active Trials
NCT05966480Active Not Recruiting408Est. Sep 2027
Pfizer
PfizerNEW YORK, NY
1 program
No Medical InterventionN/A

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
AlumisESK-001

Clinical Trials (1)

Total enrollment: 408 patients across 1 trials

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Start: Jun 2023Est. completion: Sep 2027408 patients
Phase 2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space